Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that primarily affects the joints and may cause progressive joint damage and disability. As per Joshua J. Skydel et al. (2024), RA is the most common type of autoimmune arthritis, affecting up to 1% of the global population. This autoimmune disease burden underlines the importance of effective treatment and ongoing epidemiological assessment.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Rheumatoid Arthritis – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rheumatoid Arthritis Epidemiology Forecast Report Coverage

Expert Market Research's “Rheumatoid Arthritis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of rheumatoid arthritis. It projects the future incidence and prevalence rates of rheumatoid arthritis cases across various populations. The study covers age, gender, and type as major determinants of the rheumatoid arthritis population. The report highlights patterns in the prevalence of rheumatoid arthritis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of rheumatoid arthritis in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Rheumatoid Arthritis Understanding: Disease Overview

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease in which the immune system mistakenly attacks the synovial lining of joints, causing inflammation, pain, swelling, and progressive joint damage. It develops through interactions among genetic susceptibility, environmental exposures, and immune dysregulation. Although it primarily affects the joints, it can also involve organs such as the lungs, heart, and eyes. Clinical patterns include seropositive rheumatoid arthritis, characterized by detectable rheumatoid factor or anti-citrullinated protein antibodies, and seronegative disease, in which these antibodies are absent despite compatible clinical findings.

Key Report Insights

Parameter

Insight

Largest Patient Pool

India

Fastest Growing Country

India

High-Risk Population

Women, older adults, individuals with a family history of rheumatoid arthritis, and people who smoke.

Key Diagnostic Method

Clinical examination, rheumatoid factor testing, anti-cyclic citrullinated peptide antibody testing, inflammatory markers, and imaging.

Major Risk Factor

Genetic susceptibility, cigarette smoking, female sex, increasing age, and environmental exposures.

Major gap in the market

Delayed diagnosis, limited access to specialist care, and affordability barriers to long-term treatment, particularly biologic therapies.

Rheumatoid Arthritis Epidemiology Perspective

The rheumatoid arthritis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the rheumatoid arthritis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for rheumatoid arthritis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Joshua J. Skydel et al. (2024), rheumatoid arthritis affects up to 1% of the global population. Healthline Media UK Ltd. also reports an estimated 1.3 million affected individuals in the United States, representing approximately 0.6%-1% of its population.

Gender-Specific Cases of the Disease

According to the World Health Organization (WHO), approximately 70% of people living with rheumatoid arthritis are women. This indicates a substantial gender difference in the disease burden, with women representing the majority of affected individuals.

Age-Specific Cases of the Disease

As per the World Health Organization, approximately 55% of people living with rheumatoid arthritis are older than 55 years. The disease burden therefore includes a considerable proportion of older adults, making age distribution an important epidemiological consideration.

Ethnicity-Wise Cases of the Disease

Epidemiological patterns may vary across populations because of differences in population characteristics, environmental exposures, and healthcare access. The supplied data does not establish rheumatoid arthritis-specific prevalence percentages for individual ethnic groups.

Mortality and Survival Analysis of the Disease

Rheumatoid arthritis contributes to long-term disease burden and may affect quality of life and socioeconomic outcomes. According to Chandrashekara et al. (2024), the disease has substantial individual and healthcare-system implications in India. The supplied data does not quantify rheumatoid arthritis-specific mortality or survival rates.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Seropositive rheumatoid arthritis

Seropositive rheumatoid arthritis is characterized by positive rheumatoid factor or anti-cyclic citrullinated peptide antibodies. The supplied information indicates that it accounts for the majority of rheumatoid arthritis cases but does not provide a verified percentage.

Seronegative rheumatoid arthritis

Seronegative rheumatoid arthritis involves rheumatoid arthritis symptoms despite negative rheumatoid factor and anti-cyclic citrullinated peptide antibody tests. The supplied information does not establish a precise prevalence percentage for this subtype.

Palindromic rheumatism

Palindromic rheumatism is a rare, episodic condition involving intermittent inflammatory attacks. The supplied information suggests that approximately 10% of classic rheumatoid arthritis cases begin with palindromic-style episodes.

Rheumatoid Arthritis – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Rheumatoid Arthritis Epidemiology

The rheumatoid arthritis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Healthline Media UK Ltd., approximately 1.3 million people in the United States have rheumatoid arthritis, representing an estimated 0.6%-1% of the population. This provides a country-specific indication of the disease burden.

Germany

As per the European Medicines Agency (EMA), rheumatoid arthritis prevalence in Germany is estimated at 0.8%, corresponding to approximately 560,000 patients among 69.4 million inhabitants. Around 25% of these patients receive advanced disease-modifying antirheumatic drug treatments.

France

According to Cécile Gaujoux-Viala et al. (2023), rheumatoid arthritis affects approximately 200,000 patients in France. This estimate indicates a substantial diagnosed patient population and provides a reference point for assessing national disease burden.

Italy

The rheumatoid arthritis burden in Italy is influenced by an aging population, the higher occurrence of the disease among women, and environmental risk factors such as smoking. Improved diagnostic practices and greater use of specialized rheumatology services may also increase the identification of cases.

Spain

The burden of in Spain is shaped by population aging, gender-related differences in susceptibility, smoking exposure, and excess body weight. Access to early arthritis clinics and improved recognition of symptoms can support earlier diagnosis and increase the number of identified cases.

United Kingdom

Rheumatoid arthritis prevalence in the United Kingdom is influenced by an aging population, female predominance, genetic susceptibility, and environmental exposures, particularly smoking. Differences in awareness, early referral, and access to rheumatology assessment may also affect diagnosis rates and the number of recognized cases.

Japan

According to Toshihiro Matsui et al. (2025), a national rheumatoid arthritis cohort included 26,607 patients, with a mean age of 64.16 years; 78.87% were women. These figures describe the study cohort rather than national population prevalence.

India

According to Chandrashekara et al. (2024), rheumatoid arthritis has an estimated prevalence of 0.75% in India, affecting approximately 5-7 million individuals. The disease also imposes substantial socioeconomic and healthcare burdens.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Rheumatoid arthritis management across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India presents opportunities to improve early diagnosis, treatment access, and long-term disease control. In India, rising disease burden and substantial regional variation highlight the need for stronger awareness, timely referral, and access to rheumatology services. Across these markets, biologic disease-modifying antirheumatic drugs offer treatment options for patients with inadequate responses to conventional therapies. Opportunities include improving treatment affordability, optimizing patient selection, and supporting sustained disease monitoring.

Rheumatoid Arthritis: Treatment Overview

Rheumatoid arthritis treatment aims to control inflammation, prevent irreversible joint damage, maintain physical function, and achieve sustained remission or low disease activity. Disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, are commonly used as initial therapy. Biologic DMARDs, including tumor necrosis factor inhibitors, interleukin-6 inhibitors, and other targeted agents, may be prescribed when conventional treatment is insufficient. Targeted synthetic DMARDs, such as Janus kinase inhibitors, provide additional options for selected patients. Nonsteroidal anti-inflammatory drugs and corticosteroids may help manage symptoms or short-term flares, while treat-to-target therapy supports regular disease assessment and treatment adjustment.

Key Questions Answered

  • What is the current and projected burden of rheumatoid arthritis across the 8 major markets?
  • Which countries across the 8 major markets account for the highest rheumatoid arthritis patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of rheumatoid arthritis across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of rheumatoid arthritis across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of rheumatoid arthritis across the 8 major markets?
  • How do major comorbidities and risk factors influence rheumatoid arthritis epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of rheumatoid arthritis across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the rheumatoid arthritis landscape across the 8 major markets?
  • Which therapeutic areas linked to rheumatoid arthritis are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the rheumatoid arthritis epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on rheumatoid arthritis epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for rheumatoid arthritis across the 8 major markets?

Scope of the Rheumatoid Arthritis Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of rheumatoid arthritis based on several factors.
  • Rheumatoid Arthritis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The rheumatoid arthritis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Argentina Systemic Lupus Erythematosus Market

Brazil Systemic Lupus Erythematosus Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us